Product Images Pemetrexed

This is a description of Pemetrexed, a cytotoxic agent for intravenous use only. It comes in a single-dose vial containing 1 gram of the drug. The recommended dosage is to add 0.9% sodium chloride solution to the vial, making sure to discard any unused portion. Storage should be at room temperature not exceeding 25°C. Caution should be exercised when handling the drug. The text includes the product name, dosage information, storage requirements, and handling precautions.*

This is a description of Pemetrexed for Injection, a medication available in single-dose vials. Each vial contains 1 gram of Pemetrexed disodium and 1 gram of mannitol. The pH may have been adjusted using Hydrochloric acid and/or sodium hydroxide. The powder should be stored at temperatures between 25°C (77°F) with excursions permitted to 15-30°C (59 to 86°F). Reconstituted and infusion solutions should be stored at 2 to 8°C (36 to 46°F). Any unused portion should be discarded. The manufacturer is Accord Healthcare Inc. for Intas Pharmaceuticals Limited, based in India. The medication is for intravenous use only and is categorized as a cytotoxic agent.*

The text seems to be describing a medication called "Pemetrexed" that comes in a single-dose vial for intravenous use. It also includes instructions for reconstitution and storage of the medication. Additionally, there is a cautionary note regarding its cytotoxic nature. However, the initial and ending lines make no sense.*

This is a description of Pemetrexed, a drug for intravenous use only that comes in single-dose vials. Each vial contains 500 mg of Pemetrexed disodium and 500 mg of Mannitol. It is recommended to store the powder at a temperature between 15°C and 30°C (59 to 85°F) and the reconstituted and infusion solutions should be refrigerated at 2 to 8°C (36 to 46°F). Hydrochloric acid and sodium hydroxide may have been added to adjust the pH. The unused portion of the drug should be discarded. It is an oncology drug and should be handled with caution. The manufacturer is Accord Healthcare Inc., Durham, NC, and the manufacturer of the active ingredient is Intas Pharmaceuticals Limited, Ahmedabad, India. NDC code for Pemetrexed is 16729-280-11.*

This appears to be a table of cancer treatments and survival times. Two treatments are compared, "pemetrexed and cisplatin" versus "gemcitabine and cisplatin". The column headers include "Survival Time (months)" and "Patients at Risk". The table shows the number of patients at risk for each treatment at different time intervals up to 30 months. The table may be part of a clinical trial report.*

This appears to be a table showing the survival probability of patients receiving different combinations of chemotherapy drugs (Pemetrexed + Cisplatin and Gemcitabine + Cisplatin) at different points in time (3, 6, 9, 12, 15, and 18 months). The table also includes the number of patients at risk (for each combination), survival time in months, and patient numbers at each time point.*

This is a survival probability table which shows the survival time (in months) of patients under two treatments: Pemetexed and Paccbo. The table also shows the number of patients at risk for the specified time duration.*

This appears to be a table showing the survival time in months and patients at risk for two different treatments: Pemetexed and Pacbo. The first row likely represents the months in which survival probabilities were observed. The rest of the table seems to display the number of patients for each treatment group that were still alive at various points throughout the observation period.*

This is a chart showing the survival probability and time for two patient groups, Pemetexed and Pacsbo. The X-axis represents Survival Time in months, and the Y-axis represents Patients at Risk. The numbers on the Y-axis indicate the number of patients who have reached that point in time. However, the other text appears to be gibberish and not readable, so further information cannot be provided.*

This is a survival probability chart that shows the number of patients at risk in a study that used Cisplatin and Pemetrexed+Cisplatin for treatment. It contains survival times in months and the corresponding number of patients.*